Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.
Events & Presentations
May 15, 2019 at 5:00 PM PDT
Mar 31, 2019
Mar 11, 2019 at 4:50 PM EDT
May 13, 2019Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update
May 8, 2019Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
April 8, 2019Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer